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The  asymptomatic  phase  of  HIV-1  infections  is characterised  by  a stable  set-point  viral  load  (SPVL)  within
patients.  The  SPVL  is  a strong  predictor  of  disease  progression  and  shows  considerable  variation  of multi-
ple  orders  of  magnitude  between  patients.  Recent  studies  have  found  that the  SPVL  in donor  and  recipient
pairs  is strongly  correlated  indicating  that  the  virus  genotype  strongly  inﬂuences  viral  load.  Viral  genetic
factors  that  increase  both  viral  load  and  the  replicative  capacity  of the  virus  would  result in rapid  within-
host  evolution  to  higher  viral  loads.  Reconciling  a stable  SPVL  over  time  with  high  SPVL  heritability
requires  viral  genetic  factors  that  strongly  inﬂuence  SPVL  but only  weakly  inﬂuence  the  competitive
ability  of  the  virus  within  hosts.  We propose  a virus  trait  that affects  the  activation  of  target  cells,  and
therefore  viral  load,  but does  not  confer  a  competitive  advantage  to the  virus.  We  incorporate  this  virus-
induced  target  cell  activation  into  within-  and  between-host  models  and  determine  its  effect  on  the
competitive  ability  of  virus  strains  and  on  the  variation  in  SPVL  in  the host  population.  On  the  within-
host  level,  our  results  show  that  higher  rates  of virus-induced  target  cell  activation  increase  the SPVL and
confer no  selective  advantage  to  the  virus.  This  leads  to  a build  up  of diversity  in  target  cell  activation
rates  in  the  virus  population  during  within-host  evolution.  On  the  between-host  level, higher  rates  of
target  cell  activation  and  therefore  higher  SPVL  affect  the  transmission  potential  of the  virus. Random
selection  of a new  founder  strain  from  the  diverse  virus  population  within  a donor  results  in a  standing
variation  in  SPVL  in the  host  population.  Therefore,  virus-induced  target  cell  activation  can  explain  the
heritability  of  SPVL,  the  absence  of evolution  to higher  viral  loads  during  infection  and a large standing
variation  in  SPVL  between  hosts.ntroduction
The course of an HIV-1 infection is divided into three stages
haracterised in part by their viral load. The viral load sharply
ncreases during the primary infection period and then declines
o reach a quasi-steady state level in the asymptomatic phase last-
ng a few years up to several decades before it increases again in
he AIDS phase. During the asymptomatic phase the viral load ﬂuc-
uates around a stable set-point viral load (SPVL) (Geskus et al.,
007). The magnitude of these ﬂuctuations is small compared to
he large variation of several orders of magnitude, which can be
bserved between patients (102–106 copies/ml) (Bonhoeffer et al.,
003; Fraser et al., 2007; Hockett et al., 1999; Mellors et al., 1996).
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The SPVL is an important predictor of disease progression and
a good proxy for virulence. Patients with higher SPVL progress
faster towards AIDS (Mellors et al., 1996; Lavreys et al., 2006; Lyles
et al., 2000) and have a higher chance per sexual contact to infect
other people (Lingappa et al., 2010; Quinn et al., 2000). Therefore,
understanding the mechanisms that shape SPVL is essential for the
management of the disease.
Genome wide association studies have shown that host genetics
and demography together can explain up to 22% of the variation in
SPVL (Fellay et al., 2007, 2009). A number of recent studies have
found a correlation in SPVL between donor and recipients, imply-
ing that also virus genetics strongly contribute to the variation in
SPVL (Müller et al., 2011). The contribution of viral genetics to
viral load variation is commonly quantiﬁed as the heritability of
SPVL, which is deﬁned as the proportion of variance in SPVL that
is explained by variance in viral genetic factors (Visscher et al.,
2008). Different methods in different patient cohorts quantiﬁed
Open access under CC BY license.the heritability of SPVL and found estimates ranging from 0.2 to
0.6 (Müller et al., 2011; Alizon et al., 2010; Hollingsworth et al.,
2010), although there is some inconsistency in the literature with
regard to using correlation coefﬁcient, the regression slope or the
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oefﬁcient of determination as a measure of heritability (Müller
t al., 2011). What virus genetic factors control viral load remains
nclear. Higher viral load (i.e. counts of viral RNA copies) could
rise from an increase in replicative capacity (Kouyos et al., 2011).
n this case, virus genotypes that cause a higher viral load would
ave a competitive advantage over genotypes that cause a lower
iral load.
The genetic diversity of HIV within a patient is large as HIV is
rone to errors during replication (Overbaugh and Bangham, 2001;
ambaut et al., 2004). Furthermore, the virus population has a high
urnover with a mean half-life of 1–2 days (Cofﬁn, 1995; Ho et al.,
995; Perelson et al., 1996; Wei  et al., 1995). The high heritabil-
ty, the ﬁtness differences between virus genotypes, the large virus
opulation size within a host, the high mutation rate and the short
eneration time together lead to the expectation that within-host
volution should lead to higher viral loads over the long dura-
ion of the asymptomatic phase (Read and Taylor, 2001). Although
PVL increases slightly over the course of an infection, we  do not
bserve a strong increase in viral load during the asymptomatic
hase (Geskus et al., 2007).
One way to reconcile the contrasting observations of a high
apacity for rapid evolution but the absence of strong within-
ost evolution towards higher viral load is to hypothesise that
he genetic factors that control SPVL do not confer a competitive
dvantage to the virus on the within-host level. This is in con-
rast to viral traits that may  inﬂuence SPVL (e.g. virion production,
nfectiousness, interactions with the immune system, or CTL escape
utations). These traits are beneﬁcial and would thus be selected
or during the course of an infection. The absence of large intra-host
volution, however, is an indication that these factors are unlikely
he main drivers of the between-host diversity in SPVL.
One such factor that is selectively neutral but inﬂuence SPVL
ould be viral genes that contribute to the activation rate of target
ell as activated target cells represent the pool of cells susceptible
o infection. Combining analysis of clinical data and a very generic
odelling approach Bonhoeffer et al. (2003) argued that activa-
ion rate of target cells may  be a major contributor to variation
n viral load between different patients. Clinical studies conﬁrmed
hat higher SPVL is correlated with higher activation of target
ells (Catalfamo et al., 2011) and that target cell activation is
inked to faster target cell depletion, faster disease progression and
igher transmission risk (Hazenberg et al., 2003; Lawn et al., 2001).
iancotto et al. (2008) showed that activated target cells express
ctivation markers such as CD25 or HLA-DR and are more suscep-
ible to productive infection. While it is currently unclear how and
o what extent the virus contributes to the rate of activation of tar-
et cells, there is no shortage of candidate factors (see Bartha et al.,
008). The population of activated target cells can be understood
s a public good, i.e. all virus strains within the host beneﬁt equally
rom this pool of susceptible cells regardless of how much the indi-
idual strains in the virus population contribute to the activation of
arget cells (Bartha et al., 2008; Brown, 1999). If all virus variants in
he population beneﬁt equally from the available pool of activated
arget cells, then the rate at which a virus strain activates target
ells is selectively neutral (Bartha et al., 2008). Recently, Sanjuán
t al. (Sanjuán et al., 2013) have shown that epitopes in HIV are
ore conserved when compared to HCV and argue that the activa-
ion of HIV-speciﬁc CD4 cells is therefore under positive selection.
ere we refer to the activation of both HIV-speciﬁc and non-speciﬁc
arget cells as the majority of HIV infected cells are HIV non-speciﬁc
Douek et al., 2002).
If the virus-induced target cell activation is indeed a neutral
or nearly neutral) trait within the host, then we  expect varia-
ion in the genetic factor inﬂuencing the activation rate to build
p in a virus population within the host over the course of an
nfection given the rapid turnover of the viral population. On the5 (2013) 174–180 175
between-host level, however, virus-induced target cell activation
inﬂuences viral ﬁtness as a higher target cell activation rate would
result in a higher SPVL. The virus population will evolve to a viral
load that optimises the trade-off between the transmission proba-
bility and the duration of infection (Fraser et al., 2007; Alizon et al.,
2009; Shirreff et al., 2011). We  propose that this selection for max-
imal transmission results in the evolution of intermediate rates of
virus-induced target cell activation. If the transmitted virus strain
is randomly sampled from the virus population within the donor,
then the within-host diversity in virus-induced target cell activa-
tion will lead to variation in SPVL around the optimum in the host
population.
In this study, we incorporate virus-induced target cell activation
into basic within-host and between-host models of HIV. We  inves-
tigate the effect of virus strains with different activation rates on
SPVL and their competitive ability within a host. We  incorporate
the ﬁndings from the within-host model into the between-host
model to determine how the within-host diversity translates to
variation in SPVL in the host population. In particular, we  investi-
gate whether models with virus-induced target cell activation are
compatible with stable within-host SPVL, the observed variance in
SPVL between hosts and the measured heritability.
Method
Within-host model
We extend the standard dynamical HIV model (Nowak and May,
2000) with an additional activation term of susceptible cells T that
is proportional to the number of infected cells I,
dT
dt
=  + 2II
1 + (I/K) − ıT T − ˇTI, (1)
dI
dt
= ˇTI − ıII. (2)
Considering that the dynamics of free virus are much faster than
those of the infected cells we assume that free virus and infected
cells are in quasi-steady state (Bonhoeffer et al., 1997; De Boer and
Perelson, 1998) such that the number of infected cells correlates
with viral load. Susceptible cells are activated at a constant rate ,
are lost at rate ıT and infected with rate ˇI. Infected cells are lost at
rate ıI > ıT to account for death due to infection. Susceptible cells
are additionally activated at a rate 2II/(1 + I/K)  that is proportional
to the number of infected cells and the virus-determined parameter
I, and K is a constant. For I  K the term approaches 2II, for I = K
it is II and for I  K it saturates at 2IK.
To explore the competition in the within-host environment we
developed a two-strain model distinguishing between virus strain
1 (I1) with target cell activation I,1 and virus strain 2 (I2) with target
cell activation I,2,
dT
dt
=  + 2I,1I1
1 + (I1 + I2/K)
+ 2I,2I2
1 + (I1 + I2/K)
− ıT T − ˇTI1 − ˇTI2,
(3)
dI1
dt
= ˇTI1 − ıII1, (4)Strains 1 and 2 differ only in the activation rate I. Parameters
and initial values are based on Althaus and De Boer (2011) and
are rescaled to smaller population sizes for computational reasons
(Table 1).
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Table  1
Parameters and initial values for the within-host model. The values for , ıT , ıI and ˇ
are  derived from Althaus and De Boer (Althaus and De Boer, 2011).  ˇ was calculated
using the approximation ˇ(per cell) = ˇ(per virus)p/c with p being the burst size per
infected cell and c the clearance rate of virus. t was lowered to account for additional
virus-induced activation.  and  ˇ are downscaled by the factor 1000 by which the
population size was  downscaled. T0 is described by the uninfected equilibrium given
by  iıT . I0 is chosen big enough to avoid extinction due to stochastic events in the
initial phase.
Parameter Value Explanation
T0 1400 Initial value of uninfected target cells T [cells]
I0 10 Initial value of infected target cells I [cells]
  140 Constant activation of target cells [cells d−1]
I , I,1, I,2 0–0.9 Virus-induced activation of target cells [d−1]
ıT 0.1 Net loss rate of uninfected target cells [d−1]
ıI 1.0 Death rate of infected target cells [d−1]
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P
eˇ  0.003 Infection rate per infected target cell [d−1 cell−1]
K 1000 Carrying capacity [cells]
We  developed both a deterministic and a stochastic version of
he model. We  solve the deterministic one-strain model for the
quilibrium solution (T∞, I∞) as a function of I. The equilibrium
olution of T∞ is independent of I,
∞ = 
ıT
if I0 = 0, (6)
nd T∞ = ıI
ˇ
if I0 > 0 (7)
In contrast, I∞ increases for increasing positive I and asymp-
otically approaches zero as I tends towards increasingly negative
alues,
∞ = 1
2ˇıI
(−ıIıT + ˇ − ˇıIK + 2ˇIK
+
√
4ˇıI(−ıIıT K + ˇK) + (−ıIıT + ˇ − ˇıIK + 2ˇIK)2).
(8)
∞ represents the SPVL in our model.
In the stochastic two-strain model we further investigated
he fate of a single mutant with I,m in a homogeneous resident
opulation with I,r. The analysis was conducted with three res-
dent populations (I,r = 0.15, 0.45, 0.75) and nine mutant types
I,m = 0.05, 0.15, 0.25, 0.35, 0.45, 0.55, 0.65, 0.75, 0.85). We repeated
he analysis for two different time points of introduction of the
utant: at the beginning of infection (tin = 0.01d) and at the equi-
ibrium stage (tin = 100d). We  repeated the simulation 15,000 times
or tin = 0.01d and 20,000 times for tin = 100d. The probability of
xation was calculated by dividing the number of simulations in
hich the mutant reached ﬁxation by the total number of simu-ations where ﬁxation of either type had happened before 1500d.
ore simulations are required when the mutant is introduced in
he equilibrium state since the expected probability of ﬁxation is
ower.
able 2
arameters and initial values for the between-host model. Equations and parameters to c
xtinction due to stochastic events in the initial phase. Initial values for I,pop range betw
Parameter Value Explanation
N 2000 Total population size (susceptible a
I0 90 Initial number of infected hosts [pe
I,pop – Mean virus-induced target cell act
SPVL Eqs. (6) and (7) Set-point viral load of an individua
ˇ  Eq. (8) Infectivity of an individual host [pe
ı  Eq. (9) Death rate of an individual host [a−
I 10–400 Within-host diversity in virus-indu
I * 0.1–0.75 (2013) 174–180
The models were implemented in R (R core Team, 2013). The
deSolve package (Soetaert et al., 2010) was used for the deter-
ministic model, the adaptivetau package (Johnson, 2012) for the
stochastic model.
Between-host model
We  model the between-host dynamics using a stochastic
individual-based model in a host population of constant size
N = 2000. Each host can either be susceptible or infected. The prob-
ability of being infected at a speciﬁc time point is the same for
all susceptible hosts. Birth and death of susceptible hosts are not
explicitly modelled. We  assume that removed hosts are immedi-
ately replaced by new susceptible hosts immediately replace dying
susceptible hosts. Parameter values and initial values of the vari-
ables are given in Table 2.
We only consider the asymptomatic phase of the infection such
that the whole infection of a host can be characterised by its SPVL.
The asymptomatic phase is expected to contribute most to the over-
all transmission potential due to its long duration (Hollingsworth
et al., 2008). The relative contribution of the asymptomatic stage
to the total transmission during HIV-1 infection was shown to be
71% in a serial monogamy scenario and 42% in a random mix-
ing scenario, while the primary infection accounts for 9% and 31%
respectively of the transmission in the two  scenarios, and the late-
stage infection for 20% and 27% respectively (Hollingsworth et al.,
2008). The overall transmission potential across all stages is a func-
tion of SPVL (Fraser et al., 2007).
The mean virus-induced target cell activation of all the strains
within a host, I,pop, is the only speciﬁc characteristic assigned to
an infected host. Because we do not observe signiﬁcant changes in
SPVL in patients we assume I,pop to be constant in a host over the
whole duration of infection. Since it is unclear how genetic changes
in the virus inﬂuence virus-induced target cell activation, we devel-
oped two  different models that differ in the way I,pop translates
into the SPVL of the host. We  approximate Eq. (8) using a simpliﬁed
function that translates I,pop into SPVL of a host,
SPVL = c(I,pop +
√
1 + (I,pop)2), (9)
where we  choose c = 100 resulting in realistic SPVL (I∞ between 102
and 106 cells) for values of I between 0 and 5000.
Following Fraser et al. (2007) the SPVL of a host determines both
infectiousness of an individual host,
 ˇ = (ˇmax(SPVL)
ˇk )/((SPVL)ˇk + (ˇs0)ˇk )
N
, (10)
and the death rate,
(SPVL) + (D )Dk
ı =
Dmax(DS0)
Dk
. (11)
Fraser et al. (2007) used patient data from two  different cohorts
to estimate best-ﬁt curves for the relation between SPVL and
alculate  ˇ and ı are taken from Fraser et al. (2007). I0 is chosen big enough to avoid
een R0 ≥ 0.75 R0,max.
nd infected hosts) [people]
ople]
ivation within an individual host
l host [copies ml−1]
ople−1 a−1]; described by ˇmax = 0.317 y−1, ˇ50 = 13,938 copies ml−1 and ˇk = 1.02
1]; described by Dmax = 25.4 y, D50 = 3058 copies ml−1 and Dk = 0.41
ced target cell activation
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nfectiousness, and SPVL and duration of the asymptomatic phase.
he infectiousness is derived from data on the transmission rate
ithin sero-discordant couples and was divided by the population
ize N for our model (frequency-dependent infection). The death
ate ı is the inverse of the duration of the asymptomatic phase.
he basic reproductive number R0 is ˇN/ı. The R0-curve is right-
kewed and peaks (R0,max) at a SPVL of 104.52 copies ml−1 (Fraser
t al., 2007).
At transmission, the I,pop of the recipient is sampled from the
opulation of viral strains in the donor. As it remains unclear how
enetic variation translates into variation in SPVL we  model the
ariation in I,pop within the donor using two  different models.
n the linear model we  assume that mutational changes inﬂuence
he SPVL in a linear fashion. The I,pop of the recipient is then
rawn from a normal distribution with mean I,pop of the donor
nd standard deviation I,
recipient
I,pop ∼N(donorI,pop , I). (12)
In the log-linear model the SPVL increases exponentially for
ncreasing positive I,pop,
recipient
I,pop ∼10N(log 10 donorI,pop , ∗I ). (13)
For large values of I,pop, the log-linear model is similar to the
ext-generation matrix approach of (Shirreff et al., 2011).
We initialised the system by randomly choosing I,pop for I0
nfected individuals such that their R0 ≥ 0.75 R0,max. We  conducted
n analysis of the equilibrium in dependence of I. The equilibrium
tate of the population is expected to be independent of the ini-
ial dynamics and we did not explore the initial dynamics in detail.
or the linear model we  conducted simulations with I between 10
nd 400 (10, 50, 100, 150, 200, 250, 300, 350, 400), for the log-linear
odel I* between 0.1 and 0.7 (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7). We
imulated the population until it reaches equilibrium and recorded
ean and variance of log10 SPVL during the equilibrium phase of
ll infected individuals (longitudinal data), as well as the mean val-
es of population mean and population variance of log10SPVL every
.05 time steps (cross-sectional data). We  also recorded the mean
umber of infected individuals in the equilibrium. The correlation
oefﬁcient of the log10 SPVL between all successful donor-recipient
airs in the equilibrium is an estimate of the heritability of log10
PVL, h2. We  repeated the simulation a 100 times for each I and
ook the mean of the described measures over all replicates where
he epidemic did not go extinct.
The model was implemented in R (R core Team, 2013) using the
-leap method (Gillespie, 2001).
esults
ithin-host dynamics
In the two-strain model, differences in  ˇ and ıI lead to compet-
tive exclusion of the strain with lower  ˇ or higher ıI. In contrast,
ifferences in I have no effect on the ﬁtness of individual strains
nd strains with different I coexist. I∞ in the two-strain model is
quivalent to a one-strain model with I = (I,1 + I,2)/2.
Single linear regressions for the ﬁxation probability of the dif-
erent mutants in a resident population with I,r and for the
ntroduction time point tin = 0.01d showed for I,r = 0.15 a inter-
ept of 0.10 (95% CI [0.10,0.10], p < 0.001), for I,r = 0.45 a intercept
f 0.10 (95% CI [0.09,0.10], p < 0.001) and for I,r = 0.75 a intercept
f 0.10 (95% CI [0.09,0.10], p < 0.001). For the introduction time
oint tin = 100, the single linear regressions showed for I,r = 0.15
 intercept of 0.007 (95% CI [0.005,0.008], p < 0.001), for I,r = 0.45
 intercept of 0.003 (95% CI [0.003–0.004], p-value < 0.001) and for
I,r = 0.75 a intercept of 0.001 (95% CI [0.001,0.002], p < 0.001). The5 (2013) 174–180 177
95% conﬁdence intervals for the slopes included 0 in all six regres-
sions.
We found that the ﬁxation probability of a single mutant (I,m)
in a homogeneous resident population (I,r) is well approximated
by 1/N  with N number of infected cells at the time point of intro-
duction of the mutant. The ﬁxation probability is independent of
subsequent changes in population size, which is in agreement with
the ﬁndings of Lambert (2006). If the mutant is introduced in the
initial phase of the infection (tin = 0.01d) the ﬁxation probability is
1/I0 with I0 the initial population size of infected cells (Fig. 1a). If
introduced at the equilibrium stage (tin = 100d) the ﬁxation proba-
bility is 1/I∞ with I∞ the equilibrium population size of the resident
population calculated from the deterministic model (Eq. (13)) with
I = I,r (Fig. 1b). The probability of ﬁxation of a single new mutant
is then smaller in resident populations with higher I,r (i.e. larger
population size). The probability for ﬁxation does not depend on
the value of I,m.
Between-host dynamics
We looked at the inﬂuence of the within-host diversity I
on the equilibrium state of the population. In both models,
we observed extinctions of the epidemic for large I (8/100
simulations in the linear model for I = 400, 7/100 simula-
tions in the log-linear model for I* = 0.7). The heritability
h2 of SPVL decreases with increasing I from 0.98 ± 0.00 for
I = 10 to 0.65 ± 0.00 for I = 400 in the linear model and from
0.95 ± 0.00 for I* = 0.1 to 0.72 ± 0.00 for I* = 0.7 in the log-linear
model.
The longitudinal and cross-sectional mean and variance of
log10SPVL in the infected population is shown in Fig. 2. The mean
log10SPVL deviates more strongly from the optimal log10 SPVL
(R0,max) for lower heritability h2 (Fig. 2a). The mean log10SPVL
is lower in the cross-sectional data than in the longitudinal data
since individuals with low SPVL have a longer duration of infec-
tion and are thus more likely to appear in a cross-section of
infected individuals. Individuals with high SPVL have a higher
turnover rate in the population due to their higher infectious-
ness and shorter duration of infection. Consequently, there are
more individuals with high viral load when considering all infected
individuals throughout the epidemic. Thus the longitudinal mean
log10 SPVL is both higher than the optimal log10 SPVL and higher
than the cross-sectional mean. The mean log10 SPVL is gener-
ally higher in the linear model than in the log-linear model since
choosing a new I,pop on a linear scale results in more varia-
tion in log10 SPVL below the log10 SPVL of the donor than above.
Thus, given a donor with optimal log10 SPVL, recipients that
receive a log10 SPVL below the optimum have a lower expected
ﬁtness than recipients that receive a log10 SPVL above the opti-
mum.
The variance in log10 SPVL increases with decreasing heritabil-
ity h2 for both the linear and log-linear models and in both the
cross-sectional and longitudinal data (Fig. 2b). In the linear model,
the variance in the cross-sectional data is lower than in the lon-
gitudinal data since cross-sectional data favours low log10 SPVL
individuals, thus increasing the effect of choosing a new I,pop on a
linear scale. In the log-linear model, we observed only a small dif-
ference in variance between the cross-sectional and longitudinal
data.
The number of infected individuals decreases with decreasing
h2 from 701 ± 2 for I = 10 to 132 ± 6 for I = 400 in the linear model
and from 643 ± 2 for I* = 0.1 to 131 ± 7 for I* = 0.7 in the log-linear
model. The decreasing number of infected individuals implies a
decreasing mean R0 of the infection in the population due to a
mean log10 SPVL above (or below) the optimum log10 SPVL and
a increasing variance in the population, i.e. more people infected
178 A. Hool et al. / Epidemics 5 (2013) 174–180
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iscussion
Our results conﬁrm that higher virus-induced target cell acti-
ation enhances the growth of the total virus population within
 host and leads to higher SPVL. General activation of target cells
eneﬁts all virus genotypes within a patient equally in agreement
ith (Bartha et al., 2008). Thus virus strains that cause higher tar-
et cell activation do not have any ﬁtness advantage and strains
ith different activation rates can coexist. Given the short gener-
tion time and the high mutation rate of the virus, we expect a
ast build-up of standing within-host diversity with respect to tar-
et cell activation. Only the balance between neutral mutation and
andom genetic drift which is dependent on a realistic estimate of
he effective population size inﬂuences which strain is dominant
nd how many strains coexist at the moment in the host.
In contrast to the SPVL, the uninfected target cell population
ithin a host is constant and not affected by different rates of
irus-induced target cell activation. This is in accordance with the
bserved T cell homeostasis in infected patients during the asymp-
omatic phase (Margolick et al., 1995). Higher target cell activation
ombined with T cell homeostasis is expected to lead to higher
ell turnover rates and faster depletion of the available target cell
ool, which then results in faster disease progression. If the virus
an inﬂuence the activation rate of target cells, it will have a direct
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effect on disease progression and the duration of the asymptomatic
phase.
On the between-host level, the virus population evolves to a
rate of virus-induced target cell activation that optimises its trans-
mission ﬁtness. This is compatible with Fraser et al. (Fraser et al.,
2007) who suggested that the virus evolves to optimise the trade-
off between infectiousness and duration of infection. A standing
variation of SPVL between infected hosts is maintained by drift at
transmission. More drift at transmission leads to a higher within-
host diversity in virus-induced target cell activation. Increase in
within-host diversity decreases heritability. We show that even
high heritability values result in a considerable variation in SPVL
in the infected host population and that the range variance in SPVL
is compatible with the observed variance in real populations (Fraser
et al., 2007).
The extent of the drift at transmission was also shown to deter-
mine the mean ﬁtness of the disease in the host population and
consequently the number of infected individuals.
We  consider two  different models of how mutational effects
translate into variation in viral load. The linear model that uses
a linear function treats virus-induced target cell activation as an
additive trait, while the log-linear model using an exponential func-
tion applies a multiplicative understanding. We  assumed constant
within-host diversity in virus-induced target cell activation. The
validity of this assumption, as well as the build-up of the within-
host diversity needs to be further investigated in real patients.
Continuous divergence from the founder strain and an increase and
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aturation of diversity over time were observed in the HIV-1 env
ene (Shankarappa et al., 1999) but changing selective forces during
nfection, as indicated by the changing ratio between synonymous
nd non-synonymous nucleotide substitutions in the HIV-1 env
ene (Bonhoeffer et al., 1995), suggest that neutral diversity follows
 different pattern than diversity in a trait undergoing selection.
We  ﬁnd heritability values that are larger than the heritability
easured in previous studies (Müller et al., 2011). In our model,
he only effect that decreases heritability is the drift event at trans-
ission leading to differences in the mean virus genotype between
onor and recipient. Host genotype or demography could also inﬂu-
nce SPVL and therefore decrease heritability. In this case, we
ould assume that the same mean virus genotype is transmit-
ed but that SPVL in the recipients differs from that of the donors.
ay-to-day ﬂuctuations in SPVL and measurement uncertainty can
lso decrease the heritability signal. A major question for further
esearch is whether a trait which inﬂuences SPVL and is under weak
election on the within-host level (e.g. local target cell activation
Bartha et al., 2008) or replicative capacity) would show a similar
attern on the between-host level as we could show for selectively
eutral general target cell activation. In this case, we would expect
ome standing within-host diversity (e.g. mutation-selection bal-
nce) but a changing mean during the infection due to selection.
uch a trait would remain constrained at the between-host level
ue to differences in the transmission potential and would show a
igniﬁcant level of heritability.
Different mechanisms of how the virus can inﬂuence the acti-
ation of target cells have been proposed (Bartha et al., 2008).
dentifying which viral factors are involved in virus-induced acti-
ation of target cells is important for a better understanding of
nteraction between SPVL and the pathogenesis of HIV. Genome
ide association studies that map  polymorphisms in the viral
enome onto markers of immune activation are a promising ﬁrst
tep towards identifying such viral factors.
Virus-induced target cell activation has an effect on the set-point
iral load, is heritable between infections, is selectively neutral
n the within-host level and is ﬁtness-relevant on the between-
ost level. Given these characteristics, virus-induced target cell
ctivation shows a way to reconcile high heritability, absence of
ithin-host evolution and variation in set-point viral load in the
nfected population.
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